Seres reports Q2 2023 net income of $46.6M on $125M VOWST milestone; early launch demand strong

Seres Therapeutics, Inc.

2023-Q2 EPS reported -$0.19 revenue$125,951,000

Net income $46.6M vs net loss $64.7M YoY; $125M milestone from Nestlé upon FDA approval of VOWST.
VOWST net sales $1.6M in first partial quarter; 610 prescription forms, 282 patient starts from 480+ HCPs.
Cash $229.5M; new $250M Oaktree debt facility, drew $110M at close, $53.4M to retire prior debt.
SER-155 Phase 1b Cohort 1: favorable tolerability, reduced ESKAPE pathogen domination; Cohort 2 data mid-2024.
R&D expense $46.8M, G&A $28.1M; VOWST commercial mfg costs to capitalize post-approval.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Seres Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 8, 2023, Seres Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2023 and provided operational updates.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-205557

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.